Optimized human cell products for research
and drug discovery

Scientific Advisory Board

Tamir Rashid BSc, MBBS, MRes, PhD, MRCP

Tamir Rashid obtained his doctorate in stem cell biology from the University of Cambridge, having graduated in medicine from Imperial College London (St Mary’s Hospital). He went on to complete higher specialist training in Gastroenterology & Hepatology as a Lecturer in the Department of Medicine, Cambridge before moving to King’s College London as a group leader and MRC Clinician Scientist Fellow in the newly formed Centre for Stem Cells and Regenerative Medicine. His continued interest in stem cells as a treatment for liver disorders is complimented through his clinical practice as an Honorary Consultant in the Institute of Liver Studies, King’s College Hospital. Tamir’s contributions to the stem cell and liver fields have been recognized via several prestigious awards in recent years including the American Liver Association Fellows’ Prize, the British Liver Association’s Sheila Sherlock Prize and the Academy of Medical Sciences UK Young Investigator Award. His doctoral research provided the pivotal IP leading to the spin out of DefiniGEN (Rashid et. al., JCI 2010). Tamir is an international authority on clinical applications of stem cell biology.

Roger Pedersen PhD

Roger A. Pedersen received an A.B. (with distinction) in biology from Stanford University in 1965 and a Ph.D. in biology from Yale University in 1970. He did postdoctoral work in mammalian embryology at Johns Hopkins University. In 1971, he began a research program in mammalian reproductive and developmental genetics at the University of California, San Francisco, where he explored for three decades issues of developmental potency, fate and the influence of the environment on embryonic development. That work, together with clinical service directing the UCSF in vitro fertilisation laboratory during the 1990s, led him to studies of human embryos and stem cells. In early 2001, his laboratory generated two of the human embryonic stem cell lines named on the so-called President’s list, which became eligible in late 2001 for U.S. Government funding. By then, Pedersen had relocated to the University of Cambridge in the UK, where he continues his research on human embryonic stem cells as Professor of Regenerative Medicine and Director of the Cambridge Centre for Stem Cell Biology and Medicine.